

1 An *ABCA4* loss-of-function mutation causes a canine form of Stargardt disease

2

3

4 Suvi Mäkeläinen<sup>1</sup>, Marta Gòdia<sup>1,#a</sup>, Minas Hellsand<sup>2</sup>, Agnese Viluma<sup>1</sup>, Daniela Hahn<sup>1</sup>, Karim  
5 Makdoumi<sup>3</sup>, Caroline J. Zeiss<sup>4</sup>, Cathryn Mellersh<sup>5</sup>, Sally L. Ricketts<sup>5</sup>, Kristina Narfström<sup>6</sup>,  
6 Finn Hallböök<sup>2</sup>, Björn Ekesten<sup>7</sup>, Göran Andersson<sup>1</sup>, Tomas F. Bergström<sup>1\*</sup>

7

8

9 <sup>1</sup>Department of Animal Breeding and Genetics, Swedish University of Agricultural Sciences,  
10 Uppsala, Sweden

11 <sup>2</sup>Department of Neuroscience, Uppsala University, Uppsala, Sweden

12 <sup>3</sup>Department of Ophthalmology, Faculty of Medicine and Health, Örebro University, Sweden

13 <sup>4</sup>Yale University School of Medicine, New Haven, Connecticut, United States of America

14 <sup>5</sup>Canine Genetics Research Group, Kennel Club Genetics Centre, Animal Health Trust,  
15 Lanwades Park, Kentford, Newmarket, Suffolk, United Kingdom

16 <sup>6</sup>Section for Comparative Ophthalmology, College of Veterinary Medicine, University of  
17 Missouri-Columbia. Missouri, United States of America

18 <sup>7</sup>Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala,  
19 Sweden

20 <sup>#a</sup>Current Address: Department of Animal Genomics, Centre for Research in Agricultural  
21 Genomics (CRAG) CSIC-IRTA-UAB-UB, Campus UAB, Bellaterra, Spain

22

23 \*Corresponding author

24 E-mail: [tomas.bergstrom@slu.se](mailto:tomas.bergstrom@slu.se) (TB)

25

26

27 **Abstract**

28 Autosomal recessive retinal degenerative diseases cause visual impairment and blindness in  
29 humans and dogs. Currently, no standard treatment is available but pioneering gene therapy-  
30 based canine models have been instrumental for clinical trials in humans. To study a novel  
31 form of retinal degeneration in Labrador retriever dogs with clinical signs indicating cone and  
32 rod degeneration, we used whole-genome sequencing of an affected sib-pair and their  
33 unaffected parents. A frameshift insertion in the ATP binding cassette subfamily A member 4  
34 (*ABCA4*) gene (c.4176insC), leading to a premature stop codon in exon 28 (p.F1393Lfs1395)  
35 was identified. In contrast to unaffected dogs, no full-length *ABCA4* protein was detected in  
36 the retina of an affected dog. The *ABCA4* gene encodes a membrane transporter protein  
37 localized in the outer segments of rod and cone photoreceptors. In humans, the *ABCA4* gene  
38 is associated with Stargardt disease (STGD), an autosomal recessive retinal degeneration  
39 leading to central visual impairment. A hallmark of STGD is the accumulation of lipofuscin  
40 deposits in the retinal pigment epithelium. The discovery of a canine homozygous *ABCA4*  
41 loss-of-function mutation may advance the development of dog as a large animal model for  
42 human STGD.

43

44 **Author summary**

45 Stargardt disease (STGD) is the most common inherited retinal disease causing visual  
46 impairment and blindness in children and young adults, affecting 1 in 8-10 thousand people.  
47 For other inherited retinal diseases, the dog has become an established comparative animal  
48 model, both for identifying the underlying genetic causes and for developing new treatment  
49 methods.

50 To date, there is no standard treatment for STGD and the mouse model is the only available  
51 animal model to study the disease. As a nocturnal animal, the morphology of the mouse eye  
52 differs from humans and therefore the mouse model is not ideal for developing methods for  
53 treatment. We have studied a novel form of retinal degeneration in Labrador retrievers  
54 showing clinical signs similar to human STGD. To investigate the genetic cause of the  
55 disease, we used whole-genome sequencing of a family quartet including two affected  
56 offspring and their unaffected parents. This led to the identification of a loss-of-function  
57 mutation in the *ABCA4* gene. The findings of this study may enable the development of a  
58 canine model for human STGD.

59

## 60 **Introduction**

61 Inherited retinal dystrophies are a genetically and clinically heterogeneous group of eye  
62 diseases leading to severe visual impairment in both humans and dogs [1-7]. These diseases  
63 include various forms of retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), age-  
64 related macular degeneration (AMD), cone-rod dystrophies (CRD), and Stargardt disease  
65 (STGD) and are caused by many different mutations leading to deterioration of neuroretinal  
66 and retinal pigment epithelial (RPE) function. Over 100 years ago, progressive retinal  
67 atrophy (PRA) was described as a canine equivalent of human RP [8] and is today the most  
68 common inherited retinal degenerative disease in dogs [9]. The shared phenotypic similarity  
69 of inherited retinal dystrophies in dogs and humans has made canine models attractive for  
70 gene discovery and for experimental treatments, including gene therapy, of inherited  
71 degenerative retinal disease [1, 7, 10-13]. The development of gene therapy for *RPE65*-  
72 mediated LCA is an example where a canine comparative model has been instrumental for  
73 proof-of-principle trials [10, 11, 14-16]. The identification of the p.C2Y mutation (OMIM:  
74 610598.0001) in the *PRCD* gene is another illustrative example of the benefits of using

75 canine genetics to find homologous candidate genes for human retinal dystrophies; the *PRCD*  
76 gene was initially mapped and identified in PRA affected dogs and subsequently in a human  
77 family with RP [17]. This mutation segregates in multiple dog breeds, including the Labrador  
78 retriever, where no other causative genetic variants for inherited retinal degenerations have  
79 been identified. In this study, a Labrador retriever sib-pair, one male and one female,  
80 negative for the p.C2Y mutation, was diagnosed with a novel form of retinal disease. To  
81 identify genetic variants associated with this novel canine retinal disease, we performed  
82 whole-genome sequencing (WGS) of the two affected individuals and their unaffected  
83 parents.

84

## 85 **Results and discussion**

86 The affected dogs were visually impaired under both daylight and dim light conditions.  
87 Ophthalmoscopy revealed abnormal mottling of both central and peripheral retina, reduced  
88 reflection of light, as well as subtle retinal vascular attenuation (**Fig 1a**). A patchy outer  
89 retinal atrophy was observed with optical coherence tomography (OCT) (**Fig 1b**). In contrast,  
90 retinal layering and thickness of both outer and inner retinal layers appeared similar in an  
91 unaffected dog and a carrier (**Fig 1b**). Compared to a retina of a normal dog (**Fig 1c**), loss of  
92 cones, less densely packed photoreceptor nuclei, increased lipofuscin accumulation in the  
93 RPE, as well as multifocal RPE hyperplasia and hypertrophy with focal atrophy of the  
94 overlying neuroretina were observed with light-microscopy in the affected male (**Fig 1d**). We  
95 used flash-electroretinography (FERG) to study the photoreceptor function in the three dogs.  
96 The inclination of the first part of the a-waves of the dark-adapted FERG in response to a  
97 bright flash was less steep and the amplitude of the a-waves were lower in both a carrier and  
98 an affected dog compared to the age-matched unaffected dog (**Fig 1e**). The a-wave of the  
99 affected dog is widened with longer implicit time. Furthermore, oscillatory potentials are less

100 conspicuous and the first part of the b-wave is essentially lost (**Fig 1e**). Light-adapted cone  
101 transient responses (**Fig 1f**) and cone flicker (**Fig 1g**) were profoundly abnormal in the  
102 affected dog, but considerably closer to normal in the carrier. In summary, FERG  
103 demonstrated loss of cone function and abnormal rod responses, including abnormally slow  
104 dark-adaptation in the affected dog (**Fig 1e-g**). Taken together, clinical features were atypical  
105 for PRA, but showed similarities to human STGD.

106

107 The WGS of the family quartet resulted in an average coverage of 18.2x (**S1 Table**) and the  
108 identification of  $6.0 \times 10^6$  single nucleotide variants (SNVs) and  $1.9 \times 10^6$  insertions/deletions  
109 (INDELs), of which 48,299 SNVs and 5,289 INDELs were exonic. We used conditional  
110 filtering to identify 322 SNVs (of which 117 were nonsynonymous) and 21 INDELs that  
111 were consistent with an autosomal recessive pattern of inheritance (**S2 Table**). To further  
112 reduce the number of candidate variants, we compared the positions of the variants to 23  
113 additional dog genome sequences to identify 18 nonsynonymous SNVs in 13 different genes  
114 and four INDELs in four genes that were private to the Labrador retriever family (**S2 and S3**  
115 **Tables**). Fourteen of these genes were not strong candidates based on reported function and  
116 predicted effect and were not considered further. The remaining three genes, *KIAA1549*,  
117 Usherin (*USH2A*), and ATP binding cassette subfamily A member 4 (*ABCA4*) are listed in  
118 the Retinal Information Network (RetNet) database as associated with human retinal diseases  
119 and thus considered as causative candidates for canine retinal degeneration[18]. However, the  
120 variant at the *KIAA1549* gene was predicted to have a neutral effect on the protein structure  
121 (PROVEAN score -2.333, Polyphen-2 score 0.065) and was therefore discarded. The genetic  
122 variants in the *USH2A* (exon 43; c.7244C>T) and *ABCA4* (exon 28; c.4176insC) genes were  
123 validated by Sanger sequencing. Mutations in the *USH2A* gene are associated with Usher  
124 syndrome and RP, resulting in hearing loss and visual impairment [19]. The identified

125 nonsynonymous substitution in the *USH2A* was scored as “probably damaging” using  
126 Polyphen-2 (score of 0.97) and as “deleterious” using PROVEAN (score of -4.933) (**S3**  
127 **Table**). Next, we evaluated if the genetic variants of *USH2A* and *ABCA4* were concordant  
128 with the disease by genotyping eight additional clinically affected and thirteen unaffected  
129 Labradors. Out of these dogs, 16 were related to the family quartet used in the WGS (**S1 Fig**).  
130 The *USH2A* variant was discordant with the disease phenotype and was therefore excluded  
131 from further analysis (**S4 Table**). In contrast, all eight affected individuals were homozygous  
132 for the *ABCA4* insertion and the 13 unaffected individuals were either heterozygous or  
133 homozygous for the wild-type allele (**S4 Table**).

134

135 In the *ABCA4* gene, we identified a single base pair insertion of a cytosine (C) in a cytosine  
136 mononucleotide-repeat region in exon 28, where the canine reference sequence consists of  
137 seven cytosines (CanFam3.1 Chr6:55,146,549-55,146,555) (**Fig 2a**). The insertion in this  
138 region results in a non-synonymous substitution at the first codon downstream of the repeat  
139 (c.4176insC), and subsequently leads to a premature stop codon (p.F1393Lfs\*1395) (**Fig 2c**).  
140 If translated, this would result in a truncation of the last 873 amino acids of the wild-type  
141 *ABCA4* protein (**Fig 2b-c**). Both the human and the dog *ABCA4* gene consists of 50 exons  
142 and encodes a ~250 kDa ABC transporter protein (**Fig 2d**) (human and dog *ABCA4* consists  
143 of 2,273 and 2,269 amino acid residues, respectively) [20, 21]. *ABCA4* is localized to the  
144 disc membranes of photoreceptor outer segments and facilitates the clearance of all-*trans*-  
145 retinal from the photoreceptor discs [22-24].

146

147 To compare retinal *ABCA4* gene expression in an affected, a carrier, and a wild-type dog, we  
148 performed quantitative RT-PCR (qPCR). Primers were designed to amplify three different  
149 regions of the gene. The amplicons spanned the 5'-end (exons 2-3), the identified insertion

150 (exons 27-28) and the 3'-end of the *ABCA4* gene (exons 47-48) (**S5 Table**). Each of the three  
151 primer pairs amplified a product of expected size in all three individuals. This suggests that  
152 despite the insertion leading to a premature stop codon in exon 28, the transcripts are  
153 correctly spliced. Relative levels of *ABCA4* mRNA were lower for the allele with the  
154 insertion in comparison to the wild-type allele (**Fig 3a**). This is consistent with nonsense-  
155 mediated decay (NMD) degrading a fraction of the transcripts with premature translation stop  
156 codon [25]. Transcripts not targeted by NMD could potentially be translated into a truncated  
157 protein of only 1,394 amino acid residues including the first extracellular domain (ECD1),  
158 the first nucleotide-binding domain (NBD1) and two membrane-spanning regions (**Fig 2b**)  
159 but lacking the second extracellular domain (ECD2) and the second nucleotide-binding  
160 domain (NBD2) [26-28] (**Fig 2b-d**). The NBDs are conserved across species and the NBD2,  
161 which is also referred to as the ATP binding cassette of the *ABCA4* protein, has been shown  
162 to be particularly critical for its function as a flippase [26, 28].

163

164 To investigate the presence of full-length protein, we performed western blot analysis using  
165 an anti-*ABCA4* antibody recognizing a C-terminal epitope and detecting a protein product  
166 with an approximate size of ~250 kDa. We observed a single, correctly-sized band in samples  
167 prepared from both wild-type and heterozygous dogs. The intensity of staining in retinal  
168 protein samples from the heterozygous individual was markedly lower in comparison to the  
169 samples from the wild-type retina (**Fig 3b**). In contrast, no band was detected in the retinal  
170 sample from the affected dog. To confirm the presence of photoreceptor cells, we used an  
171 anti-RHO antibody and detected similar levels of rhodopsin in all three samples (**Fig 3b**).  
172 These results suggest that no full-length protein product is produced as a result of the  
173 insertion leading to a frameshift and a premature stop codon.

174

175 Fluorescence histochemistry was used to analyze the ABCA4 protein expression and peanut  
176 agglutinin (PNA)-binding in retinas from three dogs with different *ABCA4* genotypes. PNA  
177 binds selectively to cones in the retina[29]. ABCA4 immunoreactivity (IR) was seen in the  
178 outer part of the neural retina and the RPE. The pattern corresponded to photoreceptor outer  
179 segments and overlapped partially with the PNA label. PNA stained cone-shaped cells  
180 spanning both the inner and outer segments (**Fig 4a**). ABCA4 IR was also seen on PNA-  
181 negative outer segments, likely to be rod photoreceptors and RPE. The ABCA4 IR and PNA  
182 patterns were similar in wild-type and heterozygous retinas. In sharp contrast, no ABCA4 IR  
183 was found in the affected retina (**Fig 4a-c**). In addition, no evident PNA-staining was  
184 observed, implying loss of cones. We therefore counted photoreceptor nuclei in the three  
185 genotypes and compared the outer and inner nuclear layers. The photoreceptor nuclei are  
186 positioned in the outer nuclear layer but not in the inner nuclear layer and there were fewer  
187 nuclei in the affected outer nuclear layer in the affected retina than in the wild-type or  
188 heterozygous retina (**Fig 4d**). The corresponding reduction of nuclei was not seen in the inner  
189 nuclear layer, suggesting that photoreceptors were affected but not neurons in the inner  
190 nuclear layer. The loss of ABCA4 protein, loss of cone outer segment-PNA-staining, and the  
191 reduction of photoreceptor nuclei in the affected retina strongly imply that photoreceptors  
192 degenerate in the *ABCA4*<sup>-/-</sup> retina.

193

194 The RPE layer of the affected retina was autofluorescent (**Fig 4c**), indicating accumulation of  
195 lipofuscin[30]. We analyzed autofluorescence in RPE from retinas of three dogs with  
196 different *ABCA4* genotypes. The autofluorescence in the affected retina was higher than in  
197 that of the retinas in the other genotypes (**Fig 4g-h**). The higher autofluorescence indicates an  
198 increased accumulation of lipofuscin in the affected retina compared to the retinas from wild-  
199 type or heterozygous individuals.



200

201 The ABCA4 protein functions as an ATP-dependent flippase in the visual cycle, transporting  
202 *N*-retinylidene-phosphatidylethanolamine (*N*-Ret-PE) from the photoreceptor disc lumen to  
203 the cytoplasmic side of the disc membrane [31, 32]. *N*-Ret-PE is a reversible adduct  
204 spontaneously formed between all-*trans*-retinal and phosphatidylethanolamine (PE), and is  
205 unable to diffuse across the membrane by itself. Once transported by ABCA4, *N*-Ret-PE is  
206 dissociated and all-*trans*-retinal will re-enter to the visual cycle [33]. Defective ABCA4 leads  
207 to accumulation of *N*-Ret-PE, which together with all-*trans*-retinal, will form di-retinoid-  
208 pyridinium-phosphatidylethanolamine (A2PE) that is further hydrolyzed to phosphatidic acid  
209 (PA) and a toxic bis-retinoid, di-retinal-pyridinium-ethanolamine (A2E) [34]. This will lead  
210 to an accumulation of A2E in RPE cells when photoreceptor discs are circadianly shed and  
211 phagocytosed by the RPE [35-37]. A2E is a major component of RPE lipofuscin, accounts  
212 for a substantial portion of its autofluorescence, and has a potentially toxic effect on the RPE  
213 leading to photoreceptor degeneration [35, 38-40]. In ABCA4-mediated diseases, cone  
214 photoreceptors are typically affected prior to rods [41]. The accumulation of lipofuscin and  
215 the degeneration of cones seen in this study of Labrador retrievers are also characteristic of  
216 STGD in humans [30, 42].

217

218 Mutations in the human *ABCA4* (*ABCR*) gene cause autosomal recessive STGD, autosomal  
219 recessive forms of CRD and RP [43-45]. The gene was first cloned and characterized in 1997  
220 [20], and 873 missense and 58 loss-of-function variants have been reported in the ExAC  
221 database [46, 47], many of which are associated with visual impairment [48-50]. Currently,  
222 there is no standard treatment for STGD in humans and *Abca4*<sup>-/-</sup> mouse is the only available  
223 animal model [51, 52]. Mice, however, lack the macula, which is primarily the area affected  
224 in STGD, and although mouse models have provided insight into genesis of the lipofuscin

225 fluorophore A2E, *Abca4*<sup>-/-</sup> mice do not exhibit a significant retinal degeneration phenotype  
226 [53, 54]. Unlike the mouse retina, the dog has a cone rich fovea-like area functionally similar  
227 to human fovea centralis [1, 3, 11]. The canine eye is also similar in size to the human eye,  
228 and dog has successfully been used for experimental gene therapy for retinal degenerations  
229 such as LCA, RP, rod-cone dysplasia type 1 (*rcd1*) [12, 16, 55]. For over a decade there has  
230 been interest in finding a canine model for *ABCA4* mediated diseases [56-58]. The loss-of-  
231 function mutation identified here can be used to develop large animal model for human  
232 STGD.

233

## 234 **Methods**

### 235 **Animals and samples**

236 A family quartet of Labrador retrievers (sire, dam, and two affected offspring numbered  
237 LAB1, LAB2, LAB3 and LAB4 respectively) were used in the whole-genome sequencing  
238 (WGS). In addition, 16 related individuals (LAB5 to LAB20, see **S1 Figure**) as well as five  
239 unrelated Labradors (LAB 21 to LAB25) were used to validate the WGS findings. Whole  
240 blood samples from these dogs were collected in EDTA tubes and genomic DNA was  
241 extracted using 1 ml blood on a QIA Symphony SP instrument and the QIA Symphony DSP  
242 DNA Kit (Qiagen). We obtained eyes from the affected male (LAB4) and his unaffected  
243 sibling (LAB6) at the age of 12, as well as from one unrelated, unaffected 11-year-old female  
244 Labrador retriever (LAB24) and one 10-year-old male German spaniel (GS) after their  
245 euthanization (with sodium pentobarbital (Pentobarbital 100 mg/ml, Apoteket Produktion  
246 & Laboratorier AB) for unrelated reasons. All samples were obtained with informed dog  
247 owner consent. Ethical approval was granted by the regional animal ethics committee  
248 (Uppsala djursförsöksetiska nämnd; Dnr C12/15).

249

250 **Ophthalmic exam and optical coherence tomography (OCT)**

251 Ophthalmic examination included reflex testing, testing of vision with falling cotton balls  
252 under dim and daylight conditions, indirect ophthalmoscopy and slit-lamp biomicroscopy.  
253 The affected male (LAB4), his unaffected sibling (LAB6) and an unaffected, age-matched,  
254 female Labrador (LAB22) were examined with spectral-domain OCT (Topcon 3D OCT-  
255 2000, Topcon Corp.). The examination was done after pupillary dilation, but without  
256 sedation, using repeated horizontal single line scans (6 mm, 1024 A-scans) (Topcon 3D  
257 OCT-2000, Topcon Corp.) along the visual streak area.

258

259 **Flash-electroretinography (FERG)**

260 We recorded FERG bilaterally from the three dogs examined with OCT under general  
261 anaesthesia. Sedation with intramuscular acepromazine 0.03 mg/kg (Plegicil vet., Pharmaxim  
262 Sweden AB) was followed by induction with propofol 10 mg/kg IV (Propovet, Orion Pharma  
263 Animal Health AB). After intubation, inhalation anaesthesia was maintained with isoflurane  
264 (Isoflo vet., Orion Pharma Animal Health AB). Corneal electrodes (ERG-JET, Cephalon  
265 A/S) were used with isotonic eye drops (Comfort Shield, i.com medical GmbH) as coupling  
266 agent. Gold plated, cutaneous electrodes served as ground and reference electrodes (Grass,  
267 Natus Neurology Inc.) at the vertex and approximately 3 cm caudal to the lateral canthi,  
268 respectively. Light stimulation, calibration of lights and processing of signals were performed  
269 as described by Karlstam et al., 2011[59]. We used a slightly modified ECVO protocol[60],  
270 where the process of dark-adaptation was monitored for 1 hour before a dark-adapted  
271 response intensity series was performed.

272

273 **Histopathology**

274 Sectioned eyes from the affected male (LAB4) and the unaffected male GS were immersed in  
275 Davidson's Solution. The eyes were dehydrated in ethanol, paraffin embedded, cut into 4  $\mu$ m  
276 thick sections and stained with haematoxylin and eosin (H&E).

277

### 278 **Whole-genome sequencing**

279 Genomic DNA from four Labrador retriever dogs (LAB1, LAB2, LAB3 and LAB4) was  
280 fragmented using the Covaris M220 instrument (Covaris Inc.), according to the  
281 manufacturer's instructions. To obtain sufficient sequence depth, we constructed two  
282 biological replicates of libraries with insert sizes of 350 bp and 550 bp following TruSeq  
283 DNA PCR-Free Library Prep protocol. The libraries were multiplexed and sequenced on a  
284 NextSeq500 instrument (Illumina) for 100 x 2 and 150 x 2 cycles using the High Output Kit  
285 and High Output Kit v2, respectively. The raw base calls were de-multiplexed and converted  
286 to fastq files using bcl2fastq v.2.15.0 (Illumina). The two sequencing runs from each  
287 individual were merged, trimmed for adapters and low-quality bases using Trimmomatic  
288 v.0.32[61], and aligned to the canine reference genome CanFam3.1 using Burrows-Wheeler  
289 Aligner (BWA) v.0.7.8[62]. Aligned reads were sorted and indexed using Samtools v.1.3[63]  
290 and duplicates were marked using Picard v.2.0.1. The BAM files were realigned and  
291 recalibrated with GATK v.3.7[64]. Multi-sample variant calling was done following GATK  
292 Best Practices [65] using publicly available genetic variation Ensembl Variation Release 88  
293 in dogs (*Canis lupus familiaris*). We filtered the variants found by GATK using the default  
294 values defining two groups of analyses: trio 1 and 2, both consisting of the same sire and  
295 dam, and one of their affected offspring. Variants annotated in the exonic region with  
296 ANNOVAR v.2017.07.16 [66], presenting an autosomal recessive inheritance pattern and  
297 shared between the two trios were selected for further evaluation. To predict the effects of  
298 amino acid changes on protein function, we evaluated SNVs using PolyPhen-2 v2.2.2r398

299 [67] and PROVEAN v.1.1.3 [68] and nonframeshift INDELS using PROVEAN v.1.1.3.  
300 Frameshift INDELS were manually inspected using The Integrative Genomics Viewer (IGV)  
301 [69, 70]. The sequence data were submitted to the European Nucleotide Archive with the  
302 accession number PRJEB26319.

303

#### 304 **Validation of the variants**

305 To validate the WGS results, we designed primers amplifying the variants c.7244C>T in  
306 *USH2A* gene and c.4176insC in *ABCA4* gene with Primer3 [71, 72] (**S5 Table**) and  
307 sequenced the family quartet using Applied Biosystems 3500 Series Genetic Analyzer  
308 (Applied Biosystems, Thermo Fisher Scientific). To test if the variants were concordant with  
309 the disease, 21 additional ophthalmologically evaluated Labrador retrievers were genotyped  
310 by Sanger sequencing. Eight of these dogs were clinically affected and thirteen showed no  
311 signs of retinal degeneration by the age of seven years.

312

#### 313 **Quantitative RT-PCR (qPCR)**

314 Neuroretinal samples were collected from the affected dog (LAB4), the heterozygous sibling  
315 (LAB6), and the unaffected female (LAB24). The samples were immediately preserved in  
316 RNAlater (SigmaAldrich), homogenized with Precellys homogenizer (Bertin Instruments)  
317 and total RNA was extracted with RNeasy mini kit (Qiagen) according to the  
318 manufacturer's instructions. RNA integrity and quality were inspected with Agilent 6000  
319 RNA Nano kit with the Agilent 2100 Bioanalyzer system (Agilent Technologies). cDNA was  
320 synthesized using RT<sup>2</sup> First Strand kit (Qiagen) with random hexamers provided in the kit.  
321 cDNA concentration was inspected with Qubit ssDNA Assay kit (Life Technologies). RT<sup>2</sup>  
322 qPCR Primer Assay (Qiagen) was used to amplify the reference gene *GAPDH*. To amplify  
323 the target gene *ABCA4*, we designed custom primers with Primer3 [71, 72] targeting three

324 different regions spanning exons 2 to 3, 27 to 28, and 47 to 48 (**S5 Table**). We amplified the  
325 cDNA fragments encoding regions of interest using RT<sup>2</sup> SYBR Green ROX qPCR  
326 Mastermix (Qiagen) with StepOnePlus Real-Time PCR system (Applied Biosystems,  
327 Thermo Fisher Scientific), according to the manufacturer's instructions. Target gene  
328 expression was normalized to expression of *GAPDH*, and shown relative to a control  
329 *ABCA4*<sup>+/+</sup> sample ( $\Delta\Delta C_T$  method). The results were confirmed in two independent  
330 experiments.

331

### 332 **SDS-Gel Electrophoresis and Western Blotting**

333 We extracted protein from the neuroretinal samples of the individuals used in qPCR (see  
334 above) by homogenization in Pierce RIPA lysis buffer (Thermo Scientific) supplemented  
335 with phosphatase inhibitor cocktail (Sigma, P8340) using the Precellys homogenizer (Bertin  
336 Instruments). Protein concentration was determined using the Pierce BSA Protein Assay kit  
337 (Thermo Fischer Scientific). 50  $\mu$ g of protein samples were resolved by SDS-PAGE,  
338 transferred to nitrocellulose membrane, and immunoblotted with the following primary  
339 antibodies: ABCA4 (Novus Biologicals, NBP1-30032, 1:1000), GAPDH (Thermo Scientific,  
340 MA5-15738, 1:1000), Rhodopsin (Novus Biologicals, NBP2-25160SS, 1:5000), followed by  
341 Anti-Mouse IgG horseradish peroxidase-conjugated secondary antibody (R&D Systems,  
342 HAF007, 1:5000). Binding was detected using the Clarity western ECL substrate (Bio-Rad).

343

### 344 **Fluorescence histochemistry**

345 Tapetal fundus from the affected male (LAB4), his heterozygous sibling (LAB6), and the  
346 unaffected GS were fixed in 4% PFA in 1x PBS on ice for 15 minutes, washed in 1x PBS for  
347 10 minutes on ice, and cryoprotected in 30% sucrose overnight at 4°C. The central part of the  
348 fundus was embedded in Neg-50<sup>TM</sup> frozen section medium (Thermo Scientific), and 10  $\mu$ m

349 sections were collected on Superfrost Plus slides (J1800AMNZ, Menzel-Gläser). The  
350 sections were re-hydrated in 1x PBS for 10 minutes, incubated in blocking solution (1%  
351 donkey serum, 0.02% thimerosal, and 0.1% Triton X-100 in 1x PBS) for 30 minutes at room  
352 temperature, and incubated in primary antibody ABCA4 (1:500, NBP1-30032,  
353 Novus Biologicals) and FITC-conjugated lectin PNA (1:400, L21409, Molecular Probes)  
354 solution at 4°C overnight. Following overnight incubation, the slides were washed 3 x 5  
355 minutes in 1x PBS and incubated in Alexa 568 secondary antibody (1:2000, A10037,  
356 Invitrogen) solution for at least 2 hours at room temperature and washed 3 x 5 minutes in 1x  
357 PBS. The slides were mounted using ProLong® Gold Antifade Mountant with DAPI  
358 (P36931, Molecular Probes). Fluorescence images were captured using a Zeiss Axioplan 2  
359 microscope equipped with an AxioCam HRc camera.

360

### 361 **Counting nuclei**

362 Ten micrometer retinal sections were mounted as described under Fluorescence  
363 histochemistry, and the number of nuclei within a region with a width of 67 µm that was  
364 perpendicular to and covered both the outer and inner nuclear layers were counted. Nuclei in  
365 the outer and inner nuclear layers were counted separately. We analysed six images from  
366 each of the three animals (LAB4, LAB6, and GS). Bar graphs were generated and statistical  
367 analysis of the technical replicates (one-way ANOVA with Tukey's post hoc multiple  
368 comparison analysis) was performed in GraphPad Prism 7.

369

### 370 **Autofluorescence**

371 Retinal sections were washed, incubated in blocking solution, and mounted as described  
372 under Fluorescence histochemistry. The exposure times for the excitation at 488 nm and  
373 568 nm were fixed for all images taken (150 ms and 80 ms, respectively). Outlines of the

374 retinal pigment epithelium (RPE), as well as adjacent background regions, were drawn using  
375 the polygon selection tool in ImageJ (v1.51, NIH), and the area and mean fluorescence  
376 intensity were measured. The mean intensity of the autofluorescence in the RPE was  
377 calculated by subtracting the background intensity from the adjacent regions. We analysed  
378 six images from each of the three individuals used in the fluorescence histochemistry. Bar  
379 graph generation and statistical analysis were performed as described under Counting nuclei.

380

381

382

### 383 **Acknowledgements**

384 The authors would like to thank the veterinary clinicians Berit Wallin-Håkansson, Ida Möller  
385 and Stuart Ellis for diagnosing and collecting samples, Anna Svensson and Kiran Kumar  
386 Jagarlamudi for technical assistance with western blotting, Mihaela Martis at the Swedish  
387 Bioinformatics Infrastructure Sweden at SciLifeLab for bioinformatics advice and Kerstin  
388 Lindblad-Toh for valuable comments of earlier versions of the manuscript. We would also  
389 like to acknowledge the support of the dedicated dog owners who allowed their dogs to take  
390 part in this study. The authors would like to acknowledge the support of the National  
391 Genomics Infrastructure (NGI) / Uppsala Genome Center and UPPMAX for providing  
392 computational infrastructure.

393

### 394 **Funding**

395 This study was funded by generous support by FORMAS, AGRIA and the Swedish Kennel  
396 Club research fund.

### 397 **Author contributions**



398 G.A. and T.B. conceived, designed and directed the study; B.E. and K.N. collected field  
399 material and diagnosed the subjects; B.E. and K.M. performed OCT, C.J.Z. performed  
400 histological analysis; C.M. and S.R. provided samples and genotypes; M.G., S.M. and D.H.  
401 performed sequencing; S.M. and M.G. performed sequence analyses and bioinformatics with  
402 support from A.V.; S.M. performed qPCR and western blotting; M.H. and F.H. performed  
403 and analyzed fluorescence histochemistry experiments; S.M., T.B. and G.A. were responsible  
404 for preparing of the manuscript with particular contributions from M.G., M.H., F.H., B.E. and  
405 C.M; all authors read and approved the final manuscript.

406

#### 407 **Competing financial interests**

408 The authors declare that the research was conducted in the absence of any commercial or  
409 financial relationships that could be construed as a potential conflict of interest. A patent  
410 application has been filed by the following authors and inventors, TB, GA, BE and SM.

411

#### 412 **Figure captions**

413 **Fig 1. Retinal morphology and function in canine Stargardt disease.** (A) The tapetal  
414 fundus of an affected dog. Black arrows indicate mottling (darker foci) and white arrows  
415 slight attenuation of the retinal blood vessels. (B) OCT images along the visual streak in age-  
416 matched unaffected dog (top), carrier (middle) and an affected dog (bottom). White arrows  
417 indicate where two images have been concatenated. A general neuroretinal thinning is visible  
418 in the affected retina (blue arrow) and includes patches of severe retinal atrophy (red arrow).  
419 (C) Histology of a normal canine retina and (D) histology of an affected retina, with red  
420 arrows indicating cone photoreceptors and black arrows indicated accumulation of lipofuscin  
421 in RPE. (E) Dark-adapted FERG in response to a bright flash (arrow) in an age-matched

422 unaffected dog (green), a carrier (blue tracing) and an affected dog (black). **(F)** Light-adapted  
423 cone transient responses and **(G)** cone flicker responses with FERG.  
424 FERG = flash-electroretinography; RPE = retinal pigment epithelium; OS = outer segments;  
425 OLM = outer limiting membrane; ONL = outer nuclear layer.

426

427 **Fig 2. Loss-of-function mutation in the canine *ABCA4* gene.** **(A)** Sanger sequencing traces  
428 spanning positions Chr6:55,146,545-55,146,564 (Canfam3.1) in exon 28 of the *ABCA4* gene  
429 of a wild-type *ABCA4*<sup>+/+</sup> dog (top), a heterozygous *ABCA4*<sup>+/-</sup> dog (middle), and a  
430 homozygous *ABCA4*<sup>-/-</sup> dog (bottom). **(B)** Predicted structure of canine full-length *ABCA4*  
431 protein, based on the proposed human structure[26], and the putative truncated product as a  
432 result of the premature stop codon at amino acid position 1,395. **(C)** Schematic representation  
433 of the region where the insertion of cytosine (C) is found showing the nucleotide and amino  
434 acid sequences of a full-length (top) and truncated (bottom) protein. **(D)** Predicted topological  
435 organization of *ABCA4* and its domains with the insertion leading to a premature stop codon  
436 marked with an arrow. The topological organization is based on the proposed human  
437 topological organization[27, 28].  
438 ECD1 = first extracellular domain; TMD1 = first membrane-spanning region; NBD1 = first  
439 nucleotide-binding domain; ECD2 = second extracellular domain; TMD2 = second  
440 membrane-spanning region; NBD2 = second nucleotide-binding domain.

441

442 **Fig 3. Characterization of *ABCA4* mRNA expression and western blot analyses of**  
443 ***ABCA4* protein levels in the canine retina.** **(A)** Relative *ABCA4* mRNA expression levels  
444 by quantitative RT-PCR in three different regions in three dogs with different genotypes  
445 (*ABCA4*<sup>+/+</sup>, *ABCA4*<sup>+/-</sup> and *ABCA4*<sup>-/-</sup>), normalized to *GAPDH* expression. **(B)** Western blot

446 analyses of ABCA4 (above), GAPDH (middle), and RHO (below) protein levels in retinal  
447 tissue.

448

449 **Fig 4. Fluorescence histochemistry of ABCA4, cone photoreceptors, and**

450 **autofluorescence in the canine retina. (A-C)** Fluorescence micrographs showing

451 ABCA4 expression (red), FITC-conjugated peanut agglutinin (PNA, green) and DAPI

452 nuclear staining (blue) in wild-type (ABCA4<sup>+/+</sup>), heterozygous (ABCA4<sup>+/-</sup>), and affected

453 (ABCA4<sup>-/-</sup>) retinas. PNA labels cone photoreceptors. Autofluorescence, indicative of

454 lipofuscin accumulation, was seen in the ABCA4<sup>-/-</sup> RPE. **(D)** Bar graph with the average

455 number of DAPI-stained nuclei within a given region of the ONL and the INL. **(E-G)**

456 Fluorescence micrographs of RPE without immunohistochemistry show autofluorescence.

457 **(H)** Bar graph with background-corrected mean autofluorescence-intensity in the RPE. Note

458 the reduction of ABCA4-immunoreactivity, PNA binding, higher autofluorescence, and

459 fewer nuclei in the ONL in the ABCA4<sup>-/-</sup> compared to ABCA4<sup>+/+</sup> or ABCA4<sup>+/-</sup> retinas. All

460 scale bars = 50  $\mu$ m; RPE = retinal pigment epithelium; ONL = outer nuclear layer; INL =

461 inner nuclear layer; Because there was only one individual per genotype, the statistics are

462 valid for the technical replicates. ANOVA with Tukey's post hoc test, n=6; \*\* $P < 0.01$ ;

463 \*\*\* $P < 0.001$ ; \*\*\*\* $P < 0.0001$ ; mean  $\pm$  S.D.

464

465

## 466 **References**

467 1. Beltran WA, Cideciyan AV, Guziewicz KE, Iwabe S, Swider M, Scott EM, et al. Canine  
468 retina has a primate fovea-like bouquet of cone photoreceptors which is affected by  
469 inherited macular degenerations. PLoS One. 2014;9(3):e90390. Epub 2014/03/07. doi:  
470 10.1371/journal.pone.0090390. PubMed PMID: 24599007; PubMed Central PMCID:  
471 PMC3944008.

- 472 2. Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal  
473 and vitreoretinal diseases. *Progress in Retinal and Eye Research*. 2010;29(5):335-75. doi:  
474 <https://doi.org/10.1016/j.preteyeres.2010.03.004>.
- 475 3. den Hollander AI, Black A, Bennett J, Cremers FPM. Lighting a candle in the dark:  
476 advances in genetics and gene therapy of recessive retinal dystrophies. *The Journal of*  
477 *Clinical Investigation*. 2010;120(9):3042-53. doi: 10.1172/JCI42258. PubMed PMID:  
478 PMC2929718.
- 479 4. Miyadera K, Kato K, Aguirre-Hernandez J, Tokuriki T, Morimoto K, Busse C, et al.  
480 Phenotypic variation and genotype-phenotype discordance in canine cone-rod dystrophy  
481 with an RPGRIP1 mutation. *Molecular vision*. 2009;15:2287-305. Epub 2009/11/26. PubMed  
482 PMID: 19936303; PubMed Central PMCID: PMCPMC2779058.
- 483 5. Downs LM, Wallin-Håkansson B, Bergström T, Mellersh CS. A novel mutation in TTC8  
484 is associated with progressive retinal atrophy in the golden retriever. *Canine Genetics and*  
485 *Epidemiology*. 2014;1:4. doi: 10.1186/2052-6687-1-4. PubMed PMID: PMC4574394.
- 486 6. Downs LM, Hitti R, Pregolato S, Mellersh CS. Genetic screening for PRA-associated  
487 mutations in multiple dog breeds shows that PRA is heterogeneous within and between  
488 breeds. *Vet Ophthalmol*. 2014;17(2):126-30. Epub 2013/11/22. doi: 10.1111/vop.12122.  
489 PubMed PMID: 24255994.
- 490 7. Beltran WA. The use of canine models of inherited retinal degeneration to test novel  
491 therapeutic approaches. *Veterinary ophthalmology*. 2009;12(3):192-204. doi:  
492 10.1111/j.1463-5224.2009.00694.x. PubMed PMID: PMC3193984.
- 493 8. Magnusson H. Uber Retinitis Pigmentosa and Konsanguinitat beim hunde. *Archiv*  
494 *fuer vergleichende Ophthalmologie*. 1911;2:147-63.
- 495 9. Miyadera K, Acland GM, Aguirre GD. Genetic and phenotypic variations of inherited  
496 retinal diseases in dogs: the power of within- and across-breed studies. *Mammalian genome*  
497 : official journal of the International Mammalian Genome Society. 2012;23(1-2):40-61. Epub  
498 2011/11/09. doi: 10.1007/s00335-011-9361-3. PubMed PMID: 22065099; PubMed Central  
499 PMCID: PMCPMC3942498.
- 500 10. Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, et al. Gene therapy  
501 restores vision in a canine model of childhood blindness. *Nat Genet*. 2001;28(1):92-5.
- 502 11. Petersen-Jones SM, Komaromy AM. Dog models for blinding inherited retinal  
503 dystrophies. *Human gene therapy Clinical development*. 2015;26(1):15-26. Epub  
504 2015/02/12. doi: 10.1089/humc.2014.155. PubMed PMID: 25671556; PubMed Central  
505 PMCID: PMCPMC4442585.
- 506 12. Occelli LM, Schon C, Seeliger MW, Biel M, Michalakakis S, Petersen-Jones S, et al. Gene  
507 Supplementation Rescues Rod Function and Preserves Photoreceptor and Retinal  
508 Morphology in Dogs, Leading the Way Towards Treating Human PDE6A-Retinitis  
509 Pigmentosa. *Human gene therapy*. 2017;28(12):1198-201. Epub 2017/12/08. doi:  
510 10.1089/hum.2017.155. PubMed PMID: 29212382.
- 511 13. Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Benniselli J, et al. Long-  
512 term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the  
513 retina in a canine model of childhood blindness. *Mol Ther*. 2005;12(6):1072-82. doi:  
514 10.1016/j.ymthe.2005.08.008.
- 515 14. Narfstrom K, Katz ML, Bragadottir R, Seeliger M, Boulanger A, Redmond TM, et al.  
516 Functional and structural recovery of the retina after gene therapy in the RPE65 null  
517 mutation dog. *Invest Ophthalmol Vis Sci*. 2003;44(4):1663-72. Epub 2003/03/27. PubMed  
518 PMID: 12657607.

- 519 15. Beltran WA, Cideciyan AV, Iwabe S, Swider M, Kosyk MS, McDaid K, et al. Successful  
520 arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene  
521 therapy to later stages of disease. *Proceedings of the National Academy of Sciences*.  
522 2015;112(43):E5844-E53. doi: 10.1073/pnas.1509914112.
- 523 16. Mowat FM, Breuwer AR, Bartoe JT, Annear MJ, Zhang Z, Smith AJ, et al. RPE65 gene  
524 therapy slows cone loss in Rpe65-deficient dogs. *Gene Therapy*. 2012;20(5):545-55. doi:  
525 10.1038/gt.2012.63  
526 <https://www.nature.com/articles/gt201263#supplementary-information>.
- 527 17. Zangerl B, Goldstein O, Philp AR, Lindauer SJP, Pearce-Kelling SE, Mullins RF, et al.  
528 Identical Mutation in a Novel Retinal Gene Causes Progressive Rod-Cone Degeneration in  
529 Dogs and Retinitis Pigmentosa in Man. *Genomics*. 2006;88(5):551-63. doi:  
530 10.1016/j.ygeno.2006.07.007. PubMed PMID: PMC3989879.
- 531 18. RetNet. Retinal Information Network [cited 2018 29 Jan]. Available from:  
532 <https://sph.uth.tmc.edu/retnet/>.
- 533 19. Mathur P, Yang J. Usher syndrome: Hearing loss, retinal degeneration and associated  
534 abnormalities. *Biochim Biophys Acta*. 2015;1852(3):406-20. doi:  
535 <https://doi.org/10.1016/j.bbadis.2014.11.020>.
- 536 20. Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram A, et al. A  
537 photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive  
538 Stargardt macular dystrophy. *Nat Genet*. 1997;15(3):236-46. Epub 1997/03/01. doi:  
539 10.1038/ng0397-236. PubMed PMID: 9054934.
- 540 21. Illing M, Molday LL, Molday RS. The 220-kDa rim protein of retinal rod outer  
541 segments is a member of the ABC transporter superfamily. *The Journal of biological*  
542 *chemistry*. 1997;272(15):10303-10. Epub 1997/04/11. PubMed PMID: 9092582.
- 543 22. Papermaster DS, Schneider BG, Zorn MA, Kraehenbuhl JP. Immunocytochemical  
544 localization of a large intrinsic membrane protein to the incisures and margins of frog rod  
545 outer segment disks. *The Journal of cell biology*. 1978;78(2):415-25. Epub 1978/08/01.  
546 PubMed PMID: 690173; PubMed Central PMCID: PMC2110123.
- 547 23. Sun H, Nathans J. Stargardt's ABCR is localized to the disc membrane of retinal rod  
548 outer segments. *Nat Genet*. 1997;17(1):15-6. Epub 1997/09/01. doi: 10.1038/ng0997-15.  
549 PubMed PMID: 9288089.
- 550 24. Quazi F, Molday RS. ATP-binding cassette transporter ABCA4 and chemical  
551 isomerization protect photoreceptor cells from the toxic accumulation of excess 11-cis-  
552 retinal. *Proc Natl Acad Sci U S A*. 2014;111(13):5024-9. Epub 2014/04/08. doi:  
553 10.1073/pnas.1400780111. PubMed PMID: 24707049; PubMed Central PMCID:  
554 PMC2977269.
- 555 25. Lykke-Andersen S, Jensen TH. Nonsense-mediated mRNA decay: an intricate  
556 machinery that shapes transcriptomes. *Nature reviews Molecular cell biology*.  
557 2015;16(11):665-77. doi: 10.1038/nrm4063  
558 <https://www.nature.com/articles/nrm4063#supplementary-information>.
- 559 26. Tsybovsky Y, Molday RS, Palczewski K. The ATP-binding cassette transporter ABCA4:  
560 structural and functional properties and role in retinal disease. *Advances in experimental*  
561 *medicine and biology*. 2010;703:105-25. Epub 2010/08/17. doi: 10.1007/978-1-4419-5635-  
562 4\_8. PubMed PMID: 20711710; PubMed Central PMCID: PMC2930353.
- 563 27. Bungert S, Molday LL, Molday RS. Membrane Topology of the ATP Binding Cassette  
564 Transporter ABCR and Its Relationship to ABC1 and Related ABCA Transporters:

- 565 identification of N-linked glycosylation sites. *The Journal of biological chemistry*.  
566 2001;276(26):23539-46. doi: 10.1074/jbc.M101902200.
- 567 28. Biswas-Fiss EE, Affet S, Ha M, Biswas SB. Retinoid binding properties of nucleotide  
568 binding domain 1 of the Stargardt disease-associated ATP binding cassette (ABC)  
569 transporter, ABCA4. *The Journal of biological chemistry*. 2012;287(53):44097-107. Epub  
570 2012/11/13. doi: 10.1074/jbc.M112.409623. PubMed PMID: 23144455; PubMed Central  
571 PMCID: PMC3531725.
- 572 29. Damiani D, Alexander JJ, O'Rourke JR, McManus M, Jadhav AP, Cepko CL, et al. Dicer  
573 inactivation leads to progressive functional and structural degeneration of the mouse retina.  
574 *J Neurosci*. 2008;28(19):4878-87. Epub 2008/05/09. doi: 10.1523/jneurosci.0828-08.2008.  
575 PubMed PMID: 18463241; PubMed Central PMCID: PMC3325486.
- 576 30. Delori FC, Staurenghi G, Arend O, Dorey CK, Goger DG, Weiter JJ. In vivo  
577 measurement of lipofuscin in Stargardt's disease - Fundus flavimaculatus. *Invest Ophthalmol*  
578 *Vis Sci*. 1995;36(11):2327-31. Epub 1995/10/01. PubMed PMID: 7558729.
- 579 31. Molday LL, Rabin AR, Molday RS. ABCR expression in foveal cone photoreceptors and  
580 its role in Stargardt macular dystrophy. *Nat Genet*. 2000;25(3):257-8. Epub 2000/07/11. doi:  
581 10.1038/77004. PubMed PMID: 10888868.
- 582 32. Quazi F, Lenevich S, Molday RS. ABCA4 is an N-retinylidene-  
583 phosphatidylethanolamine and phosphatidylethanolamine importer. *Nature*  
584 *communications*. 2012;3(925):1-9. Epub 2012/06/28. doi: 10.1038/ncomms1927. PubMed  
585 PMID: 22735453; PubMed Central PMCID: PMC3871175.
- 586 33. Kiser PD, Golczak M, Palczewski K. Chemistry of the Retinoid (Visual) Cycle. *Chem*  
587 *Rev*. 2014;114(1):194-232. doi: 10.1021/cr400107q. PubMed PMID: PMC3858459.
- 588 34. Mata NL, Weng J, Travis GH. Biosynthesis of a major lipofuscin fluorophore in mice  
589 and humans with ABCR-mediated retinal and macular degeneration. *Proc Natl Acad Sci U S*  
590 *A*. 2000;97(13):7154-9. PubMed PMID: PMC16515.
- 591 35. Weng J, Mata NL, Azarian SM, Tzekov RT, Birch DG, Travis GH. Insights into the  
592 function of Rim protein in photoreceptors and etiology of Stargardt's disease from the  
593 phenotype in abcr knockout mice. *Cell*. 1999;98(1):13-23. Epub 1999/07/21. doi:  
594 10.1016/s0092-8674(00)80602-9. PubMed PMID: 10412977.
- 595 36. Young RW. The renewal of photoreceptor cell outer segments. *The Journal of cell*  
596 *biology*. 1967;33(1):61-72. PubMed PMID: PMC2107286.
- 597 37. Young RW, Bok D. Participation of the retinal pigment epithelium in the rod outer  
598 segment renewal process. *The Journal of cell biology*. 1969;42(2):392-403. PubMed PMID:  
599 PMC2107669.
- 600 38. Eldred GE, Lasky MR. Retinal age pigments generated by self-assembling  
601 lysosomotropic detergents. *Nature*. 1993;361(6414):724-6. doi: 10.1038/361724a0.
- 602 39. Ben-Shabat S, Parish CA, Vollmer HR, Itagaki Y, Fishkin N, Nakanishi K, et al.  
603 Biosynthetic Studies of A2E, a Major Fluorophore of Retinal Pigment Epithelial Lipofuscin.  
604 *The Journal of biological chemistry*. 2002;277(9):7183-90. doi: 10.1074/jbc.M108981200.
- 605 40. Ng KP, Gugiu B, Renganathan K, Davies MW, Gu X, Crabb JS, et al. Retinal pigment  
606 epithelium lipofuscin proteomics. *Molecular & cellular proteomics : MCP*. 2008;7(7):1397-  
607 405. Epub 2008/04/26. doi: 10.1074/mcp.M700525-MCP200. PubMed PMID: 18436525;  
608 PubMed Central PMCID: PMC353379.
- 609 41. Strauss O. The Retinal Pigment Epithelium in Visual Function. *Physiol Rev*.  
610 2005;85(3):845-81. doi: 10.1152/physrev.00021.2004. PubMed PMID: 15987797.

- 611 42. Cideciyan AV, Swider M, Aleman TS, Roman MI, Sumaroka A, Schwartz SB, et al.  
612 Reduced-illumination autofluorescence imaging in ABCA4-associated retinal degenerations.  
613 *Journal of the Optical Society of America A, Optics, image science, and vision.*  
614 2007;24(5):1457-67. Epub 2007/04/13. PubMed PMID: 17429493; PubMed Central PMCID:  
615 PMC2579898.
- 616 43. Cremers FP, van de Pol DJ, van Driel M, den Hollander AI, van Haren FJ, Knoers NV, et  
617 al. Autosomal recessive retinitis pigmentosa and cone-rod dystrophy caused by splice site  
618 mutations in the Stargardt's disease gene ABCR. *Hum Mol Genet.* 1998;7(3):355-62. Epub  
619 1998/04/18. PubMed PMID: 9466990.
- 620 44. Maugeri A, Klevering BJ, Rohrschneider K, Blankenagel A, Brunner HG, Deutman AF,  
621 et al. Mutations in the ABCA4 (ABCR) Gene Are the Major Cause of Autosomal Recessive  
622 Cone-Rod Dystrophy. *Am J Hum Genet.* 2000;67(4):960-6. PubMed PMID: PMC1287897.
- 623 45. Martinez-Mir A, Paloma E, Allikmets R, Ayuso C, del Rio T, Dean M, et al. Retinitis  
624 pigmentosa caused by a homozygous mutation in the Stargardt disease gene ABCR. *Nat*  
625 *Genet.* 1998;18(1):11-2. Epub 1998/01/13. doi: 10.1038/ng0198-11. PubMed PMID:  
626 9425888.
- 627 46. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of  
628 protein-coding genetic variation in 60,706 humans. *Nature.* 2016;536(7616):285-91. doi:  
629 10.1038/nature19057  
630 <https://www.nature.com/articles/nature19057#supplementary-information>.
- 631 47. ExAC Browser. Exome Aggregation Consortium [cited 2018 29 Jan]. Available from:  
632 <http://exac.broadinstitute.org>.
- 633 48. Nasonkin I, Illing M, Koehler MR, Schmid M, Molday RS, Weber BH. Mapping of the  
634 rod photoreceptor ABC transporter (ABCR) to 1p21-p22.1 and identification of novel  
635 mutations in Stargardt's disease. *Human genetics.* 1998;102(1):21-6. Epub 1998/03/07.  
636 PubMed PMID: 9490294.
- 637 49. Rozet JM, Gerber S, Souied E, Perrault I, Chatelin S, Ghazi I, et al. Spectrum of ABCR  
638 gene mutations in autosomal recessive macular dystrophies. *European journal of human*  
639 *genetics : EJHG.* 1998;6(3):291-5. Epub 1998/10/22. doi: 10.1038/sj.ejhg.5200221. PubMed  
640 PMID: 9781034.
- 641 50. Stone EM, Webster AR, Vandenburg K, Streb LM, Hockey RR, Lotery AJ, et al. Allelic  
642 variation in ABCR associated with Stargardt disease but not age-related macular  
643 degeneration. *Nat Genet.* 1998;20(4):328-9. doi: 10.1038/3798.
- 644 51. Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. *Graefes Arch Clin*  
645 *Exp Ophthalmol.* 2017;255(6):1057-62. doi: 10.1007/s00417-017-3619-8.
- 646 52. Auricchio A, Trapani I, Allikmets R. Gene Therapy of ABCA4-Associated Diseases. *Cold*  
647 *Spring Harb Perspect Med.* 2015;5(5):a017301. doi: 10.1101/cshperspect.a017301. PubMed  
648 PMID: PMC4448589.
- 649 53. Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features,  
650 molecular genetics, animal models and therapeutic options. *Br J Ophthalmol.*  
651 2017;101(1):25-30. doi: 10.1136/bjophthalmol-2016-308823. PubMed PMID: PMC5256119.
- 652 54. Marmorstein AD, Marmorstein LY. The challenge of modeling macular degeneration  
653 in mice. *Trends Genet.* 2007;23(5):225-31. doi: <https://doi.org/10.1016/j.tig.2007.03.001>.
- 654 55. Pichard V, Provost N, Mendes-Madeira A, Libeau L, Hulin P, Tshilenge K-T, et al. AAV-  
655 mediated Gene Therapy Halts Retinal Degeneration in PDE6 $\beta$ -deficient Dogs. *Mol Ther.*  
656 2016;24(5):867-76. doi: <https://doi.org/10.1038/mt.2016.37>.

- 657 56. Zangerl B, Lindauer SJ, Acland GM, Aguirre GD. Identification of genetic variation and  
658 haplotype structure of the canine ABCA4 gene for retinal disease association studies. *Mol*  
659 *Genet Genomics*. 2010;284(4):243-50. doi: 10.1007/s00438-010-0560-5. PubMed PMID:  
660 PMC2954605.
- 661 57. Lippmann T, Pasternack SM, Kraczyk B, Dudek SE, Dekomien G. Indirect exclusion of  
662 four candidate genes for generalized progressive retinal atrophy in several breeds of dogs.  
663 *Journal of negative results in biomedicine*. 2006;5:19. Epub 2006/12/01. doi: 10.1186/1477-  
664 5751-5-19. PubMed PMID: 17134500; PubMed Central PMCID: PMC1716180.
- 665 58. Kijas JW, Zangerl B, Miller B, Nelson J, Kirkness EF, Aguirre GD, et al. Cloning of the  
666 canine ABCA4 gene and evaluation in canine cone-rod dystrophies and progressive retinal  
667 atrophies. *Molecular vision*. 2004;10:223-32. Epub 2004/04/06. PubMed PMID: 15064680.
- 668 59. Karlstam L, Hertel E, Zeiss C, Ropstad EO, Bjerkås E, Dubielzig RR, et al. A slowly  
669 progressive retinopathy in the Shetland Sheepdog. *Vet Ophthalmol*. 2011;14(4):227-38. doi:  
670 doi:10.1111/j.1463-5224.2010.00866.x.
- 671 60. Ekesten B, Komáromy AM, Ofri R, Petersen-Jones SM, Narfström K. Guidelines for  
672 clinical electroretinography in the dog: 2012 update. *Doc Ophthalmol*. 2013;127(2):79-87.  
673 doi: 10.1007/s10633-013-9388-8.
- 674 61. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina  
675 sequence data. *Bioinformatics*. 2014;30(15):2114-20. doi: 10.1093/bioinformatics/btu170.  
676 PubMed PMID: PMC4103590.
- 677 62. Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler  
678 transform. *Bioinformatics*. 2009;25(14):1754-60. doi: 10.1093/bioinformatics/btp324.  
679 PubMed PMID: PMC2705234.
- 680 63. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence  
681 Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25(16):2078-9. Epub  
682 2009/06/10. doi: 10.1093/bioinformatics/btp352. PubMed PMID: 19505943; PubMed  
683 Central PMCID: PMC2723002.
- 684 64. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The  
685 Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA  
686 sequencing data. *Genome research*. 2010;20(9):1297-303. Epub 2010/07/21. doi:  
687 10.1101/gr.107524.110. PubMed PMID: 20644199; PubMed Central PMCID:  
688 PMC2928508.
- 689 65. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework  
690 for variation discovery and genotyping using next-generation DNA sequencing data. *Nat*  
691 *Genet*. 2011;43(5):491-8. Epub 2011/04/12. doi: 10.1038/ng.806. PubMed PMID: 21478889;  
692 PubMed Central PMCID: PMC3083463.
- 693 66. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants  
694 from high-throughput sequencing data. *Nucleic acids research*. 2010;38(16):e164. Epub  
695 2010/07/06. doi: 10.1093/nar/gkq603. PubMed PMID: 20601685; PubMed Central PMCID:  
696 PMC2938201.
- 697 67. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A  
698 method and server for predicting damaging missense mutations. *Nat Methods*.  
699 2010;7(4):248-9. Epub 2010/04/01. doi: 10.1038/nmeth0410-248. PubMed PMID:  
700 20354512; PubMed Central PMCID: PMC2855889.
- 701 68. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of  
702 amino acid substitutions and indels. *PLoS One*. 2012;7(10):e46688. Epub 2012/10/12. doi:



703 10.1371/journal.pone.0046688. PubMed PMID: 23056405; PubMed Central PMCID:  
704 PMC3466303.  
705 69. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al.  
706 Integrative genomics viewer. *Nature Biotechnology*. 2011;29:24. doi: 10.1038/nbt.1754  
707 <https://www.nature.com/articles/nbt.1754#supplementary-information>.  
708 70. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-  
709 performance genomics data visualization and exploration. *Briefings in Bioinformatics*.  
710 2013;14(2):178-92. doi: 10.1093/bib/bbs017.  
711 71. Koressaar T, Remm M. Enhancements and modifications of primer design program  
712 Primer3. *Bioinformatics*. 2007;23(10):1289-91. Epub 2007/03/24. doi:  
713 10.1093/bioinformatics/btm091. PubMed PMID: 17379693.  
714 72. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al.  
715 Primer3—new capabilities and interfaces. *Nucleic acids research*. 2012;40(15):e115-e. doi:  
716 10.1093/nar/gks596. PubMed PMID: PMC3424584.  
717

718

## 719 **Supporting information**

720 **S1 Fig. Pedigree of the Labrador retriever dogs used in the study.** Filled symbols indicate  
721 affected individuals, half-filled symbols represent obligate or genotyped carriers of the  
722 *ABCA4* insertion. Individuals LAB1 to LAB4 were used in the WGS analysis. Numbered  
723 individuals were genotyped for the insertion in the *ABCA4* gene (c.4176insC) and for the  
724 non-synonymous substitution in the *USH2A* gene (c.7244C>T). In addition, five unrelated,  
725 unaffected dogs (not shown in the figure) were genotyped and found to be either wild-type or  
726 heterozygous for the variants in the *ABCA4* and the *USH2A* gene (LAB21 to LAB25).  
727 Crosses intersecting the dashed lines indicate the number of generations between the  
728 individuals.

729 **S1 Table. Summary of the whole-genome sequencing runs 1 and 2.**

730 **S2 Table. Exonic variants identified in WGS.** Number of exonic variants following  
731 autosomal recessive inheritance pattern (AR) in Trio1 and Trio2, each consisting of the  
732 parents and one of the two offspring. The total number of exonic variants in the family  
733 quartet including all inheritance patterns and the number of AR variants shared between the  
734 two trios. The "unique" column represents the number of AR variants, which were shared







735 between the two trios and not found to be homozygous in 23 additional investigated canine  
736 genome sequences.

737 **S3 Table. List of candidate variants from WGS.** Coding sequence variants identified as  
738 private for the Labrador retriever family and the predicted effect of the variants based on  
739 Polyphen-2 and PROVEAN scores.


740 **S4 Table. Validation of variants c.4176insC in ABCA4 gene and c.C7244T in USH2A**  
741 **gene by Sanger sequencing.**

742 **S5 Table. Canine primer sequences used in the analysis.**


743







**a**



**b**

